Literature DB >> 7788913

Fibrinogen after coronary angioplasty as a risk factor for restenosis.

G Montalescot1, A Ankri, E Vicaut, G Drobinski, Y Grosgogeat, D Thomas.   

Abstract

BACKGROUND: Fibrinogen is a risk factor for cardiovascular disease and is related to the severity of coronary atherosclerosis. Its role in restenosis after coronary angioplasty remains unknown. Although platelets and thrombosis contribute to the pathogenesis of restenosis, few clinical data are available concerning the relations between restenosis and proteins of the coagulation and fibrinolytic systems. METHODS AND
RESULTS: In 107 consecutive patients undergoing coronary angioplasty, we measured plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor, and fibrinogen before and immediately after angioplasty and at a 6-month follow-up. The individual changes of intraluminal diameter were measured by quantitative coronary angiography, and patients were classified according to four definitions of restenosis: (1) a final stenosis > 50%, (2) a loss of minimal luminal diameter during the follow-up period greater than the measurement variability in our laboratory (> 0.52 mm), (3) a loss of at least 50% of the gain in luminal diameter achieved by angioplasty, and (4) the combination of definitions 1 and 2. The relations between coagulation variables and each definition of restenosis were assessed univariately; then with the clinical variables included, the relations were analyzed multivariately. Angiographic follow-up was obtained in 92% of patients with a primary success of angioplasty. Global restenosis rates were 38%, 43%, 48%, and 30% for definitions 1 through 4, respectively. Plasma levels of t-PA antigen and PAI-1 antigen were not associated with any of the four definitions of restenosis. Multivariate analysis demonstrated that von Willebrand factor measured immediately after angioplasty predicted restenosis according to definitions 2 and 3. Fibrinogen measured within 6 months of follow-up was significantly increased in all restenosis groups of the four definitions. Patients with a fibrinogen concentration > 3.5 g/L at follow-up had higher restenosis rates than patients with a concentration < 3.5 g/L: 55% versus 22% (P = .001), 68% versus 31% (P = .002), 63% versus 37% (P = .01), and 74% versus 26% (P = .002) for definitions 1 through 4, respectively. The loss index was lower (P = .003) and the net gain higher (P = .03) in patients with a fibrinogen level < 3.5 g/L. There was a significant correlation between fibrinogen level and angiographic loss index (r = .41; P < .0001). Multivariate analysis confirmed that the fibrinogen level predicted restenosis with all definitions.
CONCLUSIONS: An independent relation exists between von Willebrand factor measured immediately after angioplasty and restenosis defined by the degree of intraluminal renarrowing. An elevated fibrinogen level during follow-up is a strong biochemical predictor of restenosis. Therefore, fibrinogen should be considered at least as an independent marker of restenosis and perhaps as a common risk factor for both spontaneous coronary atherosclerosis and postangioplasty restenosis, which is an accelerated form of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788913     DOI: 10.1161/01.cir.92.1.31

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery.

Authors:  M Faraggi; G Montalescot; L Sarda; J F Heintz; D Doumit; G Drobinski; I Sotirov; D Le Guludec; D Thomas
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

2.  Homocysteine: the new player in the field of coronary risk.

Authors:  G Montalescot
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

3.  Outcome of femoropopliteal angioplasty.

Authors:  J Golledge; K Ferguson; M Ellis; T Sabharwal; A H Davies; R M Greenhalgh; J T Powell
Journal:  Ann Surg       Date:  1999-01       Impact factor: 12.969

4.  Fibrinogen and cardiovascular disease.

Authors:  T W Meade
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

5.  Accelerated plasminogen activator inhibitor may prevent late restenosis after coronary stenting in acute myocardial infarction.

Authors:  Teruo Inoue; Isao Yaguchi; Keiichi Mizoguchi; Toshihiko Uchida; Kan Takayanagi; Terumi Hayashi; Shigenori Morooka; Yutaka Eguchi
Journal:  Clin Cardiol       Date:  2003-03       Impact factor: 2.882

6.  The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.

Authors:  Aleksandra A Korotaeva; Elena V Samoilova; Aleksander I Kaminny; Aleksandra A Pirkova; Therese J Resink; Paul Erne; Nina V Prokazova; Vsevolod A Tkachuk; Evgeny I Chazov
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

7.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.

Authors:  Tom Meade; Riaz Zuhrie; Claire Cook; Jackie Cooper
Journal:  BMJ       Date:  2002-11-16

8.  Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention.

Authors:  Alessandro Lupi; Gioel Gabrio Secco; Andrea Rognoni; Lidia Rossi; Maurizio Lazzero; Federico Nardi; Roberta Rolla; Giorgio Bellomo; Angelo Sante Bongo; Carlo Di Mario
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

Review 9.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

10.  Fibrinogen-dependent signaling in microvascular erythrocyte function: implications on nitric oxide efflux.

Authors:  J P Lopes de Almeida; T Freitas-Santos; C Saldanha
Journal:  J Membr Biol       Date:  2009-10-07       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.